NasdaqCM · Biotechnology

Tiziana Life Sciences (TLSA)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Buy+701.5%

$9.14 average target

$1.14+0.02 (+1.8%)Latest market snapshot · Yahoo Finance

Market cap$145.1M

Cash$4.0M

Quarterly burn—

Pipeline assets7

Short float4.7%

Latest coverage

News & Press Releases

External sources

Aug 6, 2026

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive OfficerGlobeNewswire

Jul 31, 2026

Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal ForalumabGlobeNewswire

Jul 31, 2026

Tiziana Life Sciences reports reductions in brain inflammation in third MSA patientProactive

Continue with BioPharma ProUnlock 4 more recent stories and press releases.

Unlock Pro

Company profile

About Tiziana Life Sciences

Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.